On September 26 2021 the German population voted for a change in politics. In December 2021 the new government started their work including Prof. Dr. Karl Lauterbach as their new Ministry of Health. What does this change potentially mean to the pharmaceutical industry especially for market access? Initial actions have already been concluded in the coalition contract such as an increase of the mandatory drug rebate and the change in free pricing within the AMNOG process. Listen to the opinions of German experts Dr. Stefan Walzer and Prof. Dr. Thomas Breisach.
The new one in the German Ministry of Health? All the same or significant changes?C T2023-02-12T05:18:59-05:00
Evidence Matters is a virtual one-day summit that brings the literature review community together from different industries to learn, engage, and solve ever-pressing evidence-based research challenges.
Join experts from PHAR, Novartis, and Bausch Health for a discussion around the Delphi panels and how the results are used.
Experts will present opportunities for using agile platforms and fit-for-purpose engagement models that can drive an iterative approach to obtaining payer insights and developing impactful evidence generation strategies.